Jaguar Health

$0.2123
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0214 (-9.16%) As of 10:48 AM EDT today

Why Robinhood?

You can buy or sell Jaguar Health and other stocks, options, and ETFs commission-free!

About JAGX

Jaguar Health, Inc. Common Stock, also called Jaguar Health, is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Read More Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA. The listed name for JAGX is Jaguar Health, Inc. Common Stock.

Employees
29
Headquarters
San Francisco, California
Founded
2013
Market Cap
17.86M
Price-Earnings Ratio
Dividend Yield
Average Volume
3.85M
High Today
$0.23
Low Today
$0.21
Open Price
$0.2298
Volume
2.47M
52 Week High
$1.22
52 Week Low
$0.21

Collections

JAGX Earnings

-$9.09
-$6.06
-$3.03
$0.00
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 12, Pre-Market

You May Also Like